Multiple myeloma (MM) is a malignancy of clonal plasma cells, resulting in an increased
production of ineffective immunoglobulins with suppression of non-involved …

PURPOSE: Patients with multiple myeloma are at increased risk for bacterial infection.
During the first 2 months of initial chemotherapy the rate of infection is twice that …

Objective Ascertain the benefit of prophylactic antibiotics for patients with newly diagnosed
multiple myeloma (MM), given that clinical trials evaluating this have had conflicting results …

Abstract Background TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) was a
randomised, double-blind, placebo-controlled multi-centre phase III clinical trial assessing …

Infections remain a common complication in patients with multiple myeloma (MM) and are
associated with morbidity and mortality. A risk score to predict the probability of early severe …

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To
estimate the risk of bacterial and viral infections in multiple myeloma patients, we used …

Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

The introduction of stem cell transplantation and the novel anti-myeloma agents, bortezomib,
thalidomide, and lenalidomide, have improved the outcome of patients with multiple …

We defined the epidemiology and clinical predictors of infection in patients with multiple
myeloma (MM) receiving immunomodulatory drugs (IM iDs), proteasome inhibitors (PI) and …

The clinical course of 60 patients with multiple myeloma was examined for risk factors
associated with infection. The overall incidence of infection was 1.46 per patient-year. The …